Exploring the Genetics of Schizophrenia in Manitoba (GENES-MB)
12 czerwca 2026 zaktualizowane przez: Kaarina Kowalec, University of Manitoba
Uncovering Schizophrenia Genetics Through Whole Genome Sequencing Across Manitoba
Schizophrenia is a serious mental illness that affects about 1 in 100 Canadians, shortens life expectancy, and places a large burden on individuals, families, and the healthcare system.
Genetics are known to play a major role, but current research explains only part of the inherited risk because most studies have looked at only a small portion of the genome and have mainly focused on people outside Canada.
This project will create the first large-scale Manitoba-based schizophrenia whole-genome sequencing database by studying 1,500 Manitobans with and without schizophrenia using both short-read and advanced long-read genome sequencing technologies.
Researchers will combine genetic data with lifelong provincial health records to better understand rare genetic variants linked to schizophrenia and how genetic differences influence medication response, side effects, hospitalizations, and treatment outcomes.
The study aims to fill important gaps in schizophrenia research in Canada, improve understanding of the disorder's biology, and support the development of more personalized and effective treatments for people living with schizophrenia.
Przegląd badań
Status
Jeszcze nie rekrutacja
Warunki
Szczegółowy opis
This study aims to better understand the genetic factors involved in schizophrenia by collecting saliva samples from people with schizophrenia and individuals without psychiatric disorders across Manitoba.
Researchers will use advanced genome sequencing to examine differences in genetic variation and identify genes that may contribute to schizophrenia.
By combining genetic information with health and clinical data, this research will help improve our understanding of schizophrenia and support the development of more personalized approaches to treatment and care.
People with schizophrenia (cases) will be recruited through participating psychosis clinics in Manitoba, review and sign a consent form, provide a saliva sample for genetic testing, allow researchers to use information already collected through the Manitoba Psychosis Registry and link it with health records.
People without schizophrenia or other major psychiatric disorders (screened controls) will be screened to ensure they meet eligibility requirements, review and sign a consent form, complete questionnaires about their health, quality of life, and life experiences, provide a saliva sample for genetic testing, allow researchers to link their genetic information with health records.
Objective: To understand how genes contribute to schizophrenia and psychosis by analyzing DNA samples from people with and without these conditions.
Endpoints: Collection of DNA samples, identification of genetic differences associated with schizophrenia and psychosis, and understanding how these genetic factors relate to symptoms, health outcomes, and disease risk.
Typ studiów
Obserwacyjny
Zapisy (Szacowany)
1500
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Kontakt w sprawie studiów
- Nazwa: Kaarina Kowalec, PhD
- Numer telefonu: 204-619-5711
- E-mail: kaarina.kowalec@umanitoba.ca
Lokalizacje studiów
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E0T5
- University of Manitoba
-
Kontakt:
- Danielle Perera, MSc
- Numer telefonu: 204-789-3380
- E-mail: mb.pr@umanitoba.ca
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Tak
Metoda próbkowania
Próbka bez prawdopodobieństwa
Badana populacja
The schizophrenia study population will consist of Manitoba residents aged 18 years and older with a clinical diagnosis of schizophrenia according to DSM-5 criteria.
Participants will be recruited from the MPR, including individuals receiving care through the Early Psychosis Prevention and Intervention Service (EPPIS), Schizophrenia Treatment and Education Program (STEP), Program of Assertive Community Treatment (PACT), and Assertive Community Treatment/Flexible Assertive Community Treatment (ACT/FACT) teams.
Eligible participants must be enrolled in the MPR and provide informed consent to participate in the genetic sub-study.
Participants will provide saliva samples for DNA extraction and whole genome sequencing, and their genetic data will be linked with clinical, questionnaire, and provincial administrative health data to support research on the genetic basis of schizophrenia and related health outcomes.
Opis
Inclusion Criteria:
- Individuals aged 18 years and older,
- Reside in Manitoba,
- Involved in the EPPIS, STEP, PACT, ACT/FACTT clinics,
- Clinical diagnosis of schizophrenia using standard DSM-5 criteria,
- Previously consented and enrolled in the MPR.
Exclusion Criteria:
- There are no specific exclusion criteria beyond meeting the inclusion criteria or not providing informed consent.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
Schizophrenia (cases)
The schizophrenia case group will consist of Manitoba residents aged 18 years and older who have a clinical diagnosis of schizophrenia based on standard DSM-5 criteria and who are already enrolled in the Manitoba Psychosis Registry (MPR).
Participants will be recruited through psychosis-focused clinical programs in Manitoba, including the Early Psychosis Prevention and Intervention Service (EPPIS), Schizophrenia Treatment and Education Program (STEP), Program of Assertive Community Treatment (PACT), and Assertive Community Treatment/Flexible Assertive Community Treatment (ACT/FACT) teams.
Cases will provide saliva samples for DNA extraction and whole genome sequencing, and genetic data will be linked with clinical information, questionnaire data, and provincial health administrative data to investigate the genetic basis of schizophrenia and related health outcomes.
|
|
Control (screened)
The screened control group will consist of Manitoba residents aged 40 years and older who have no known history of psychiatric disorders.
Potential controls will be identified through the Manitoba Population Research Data Repository and recruited by invitation.
Individuals will be excluded if they have had contact with a psychiatric specialist or have a history of antidepressant, lithium, mood stabilizer, or antipsychotic medication use.
Participants will provide saliva samples for DNA extraction and whole genome sequencing, and their genetic data will be linked with provincial health administrative data.
This group will serve as a comparison population for investigating genetic differences associated with schizophrenia.
|
|
Control (unscreened)
An unscreened control group of approximately 2,500 individuals from Manitoba and Saskatchewan will be included through the PrairieGen project.
These participants were sequenced using the same whole genome sequencing technologies as the study participants and represent the general Prairie population.
While no psychiatric screening or health administrative data linkage will be available for this group, they will provide a population-based genetic reference to improve statistical power and enhance the generalizability of genetic findings.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Genetic variation associated with schizophrenia
Ramy czasowe: through study completion, an average of 1 year
|
Identification of rare and common genetic variants through short-read and long-read whole genome sequencing.
Comparison of genetic variant burden between schizophrenia cases and controls.
|
through study completion, an average of 1 year
|
|
Rare variant burden in schizophrenia
Ramy czasowe: through study completion, an average of 1 year
|
Evaluation of the frequency and distribution of rare genetic variants in individuals with schizophrenia compared with controls.
|
through study completion, an average of 1 year
|
|
Pharmacogenetic associations
Ramy czasowe: through study completion, an average of 1 year
|
Identification of genetic variants associated with antipsychotic treatment response and adverse drug reactions.
|
through study completion, an average of 1 year
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Współpracownicy
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
1 sierpnia 2026
Zakończenie podstawowe (Szacowany)
1 kwietnia 2031
Ukończenie studiów (Szacowany)
1 kwietnia 2031
Daty rejestracji na studia
Pierwszy przesłany
5 czerwca 2026
Pierwszy przesłany, który spełnia kryteria kontroli jakości
12 czerwca 2026
Pierwszy wysłany (Rzeczywisty)
18 czerwca 2026
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
18 czerwca 2026
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
12 czerwca 2026
Ostatnia weryfikacja
1 czerwca 2026
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- RITHIM #4915
- PJT-206077 (Inny numer grantu/finansowania: Canadian Institutes of Health Research)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
NIEZDECYDOWANY
Opis planu IPD
IPD may or may not be shared depending on whether the participant consents to allowing sharing.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .